• Menarini and its subsidiary, Stemline were awaiting U.S. FDA approval for elacestrant ORSERDU™, a first and only oral endocrine therapy that treats advanced or metastatic breast cancer (mBC)
  • Create market shaping, visibility and awareness through broad coverage in oncology, medical and trade media publications highlighting the drug, its clinical benefits and opportunities for success as an mBC treatment
  • Use the Company’s first U.S. approval since acquiring Stemline to drive visibility for the Menarini Stemline Oncology division in U.S.

Collage of articles related to work done with Menarini

LHS Solutions

  • Conducted LHS Immersion® to solidify corporate and brand messaging and create the basis for strong storylines to key audiences
  • Identified market misperceptions and corrected them through direct engagement
  • Built communication strategies to educate HCP audiences on the clinical significance of the Phase 3 EMERALD results at key medical meetings
  • Increased U.S. brand awareness and reputation by creating foundational relationships with key oncology, medical and industry journalists
  • Developed media room materials including, fact sheets, FAQs, holding statement, biographies and images for a multimedia press release
  • Prepared the KOLs for interviews


  • Cohesive, integrated communication strategy that successfully exceeded KPIs – securing articles in 91% of oncology and industry trade pubs including Targeted Oncology, OncLive, OBR, Cure, Healio, FiercePharma, BioCentury, BioWorld, EveryDay Health
  • Positioned ORSERDU as the first new endocrine therapy in over 20 years and the only oral therapy specifically indicated for patients with ESR1-mutated advanced or metastatic breast cancer
  • Increased awareness of the ESR1 mutation and the unmet treatment need
  • Strong media coverage consisting of 763 earned and syndicated articles with over 1.25B unique visitors per month (UVM),
  • Strong journalist engagement with 9,243 shares and an audience reach of 1.69M
  • All Case Studies